English, Article edition: The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany: Economic Evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study Peter K. Schadlich; Josef Georg Brecht

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94577
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany: Economic Evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study
Author
  • Peter K. Schadlich
  • Josef Georg Brecht
Physical Description
  • article
Notes
  • Alcoholism places a considerable economic burden on society. The rate of relapse of previously weaned alcoholics has been shown to decrease following treatment with acamprosate. Therefore, this study investigated the cost effectiveness of acamprosate in the treatment of alcoholism in Germany from the perspective of the German healthcare system. In this retrospective analysis of clinical data, the additional direct medical costs per additional abstinent alcoholic incurred by adjuvant acamprosate therapy of previously weaned alcoholics were quantified. In the base-case analysis, average case-related direct costs were applied. The cost-effectiveness ratio was -2600 deutschmarks (DM) per additional abstinent patient. Thus, the administration of acamprosate is cost saving. The cost benefit of acamprosate was also shown in a sensitivity analysis. The variance of the target variable under `real world' conditions was simulated and the impact of the model variables on the target variable was quantified using a deterministic model. The variance was broad and the rate of abstinence under acamprosate was the independent variable with the greatest impact on the target variable. From the perspective of both the German healthcare system (i.e. direct medical costs) and the Statutory Health Insurance expenses, adjuvant acamprosate therapy led to net savings, while at the same time improved the patient's state of health. Based on the naturalistic design of the underlying clinical trial and on this economic evaluation, it can be concluded that adjuvant acamprosate therapy leads to net savings under `real world' conditions.
  • Alcoholism, Cost-effectiveness, Pharmacoeconomics, Acamprosate, Gaba-agonists
  • RePEc:wkh:phecon:v:13:y:1998:i:6:p:719-730
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment